Veru (VERU) Expected to Announce Quarterly Earnings on Wednesday

Veru (NASDAQ:VERU) is anticipated to issue its Q1 2026 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:00 AM ET.

Veru (NASDAQ:VERU) last announced its quarterly earnings data on Wednesday, December 17th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.18. During the same quarter in the previous year, the business earned ($0.28) EPS. On average, analysts expect Veru to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Veru Stock Performance

VERU stock opened at $2.34 on Monday. The company’s fifty day moving average price is $2.43 and its 200-day moving average price is $3.15. Veru has a one year low of $2.10 and a one year high of $7.40. The company has a market capitalization of $37.56 million, a PE ratio of -1.06 and a beta of -1.42.

Institutional Investors Weigh In On Veru

Several large investors have recently added to or reduced their stakes in VERU. XTX Topco Ltd purchased a new stake in Veru during the second quarter valued at approximately $49,000. Marshall Wace LLP bought a new position in shares of Veru during the 2nd quarter valued at approximately $220,000. Qube Research & Technologies Ltd purchased a new stake in Veru during the 2nd quarter valued at $152,000. Raymond James Financial Inc. raised its holdings in Veru by 48.3% during the 2nd quarter. Raymond James Financial Inc. now owns 206,405 shares of the company’s stock valued at $120,000 after buying an additional 67,178 shares during the period. Finally, Bank of America Corp DE lifted its position in Veru by 5.5% in the second quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock worth $108,000 after buying an additional 9,637 shares during the last quarter. 47.16% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Veru in a research note on Wednesday, January 21st. Wall Street Zen cut Veru from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Canaccord Genuity Group began coverage on Veru in a research report on Thursday, December 18th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Oppenheimer restated an “outperform” rating on shares of Veru in a report on Thursday, December 18th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.